Skip to main content
Medical information Clinical review pending

Genetic Testing

Kras Codon 61 Mutation Detection Test

The KRAS Codon 61 Mutation Detection Test identifies specific mutations in the KRAS gene, aiding oncologists in determining the most effective cancer treatment strategies for patients with certain types of cancer.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Fresh tissue in normal saline or formalin-fixed paraffin embedded (FFPE) block. Sample must contain at least 10% tumor tissue.
Results
Approximately 15 days. Confirm with the laboratory before booking.
Preparation
Confirm with the laboratory before booking. Ensure the sample is collected and transported according to laboratory guidelines. Fresh tissue should be shipped refrigerated within 72 hours.
Test priceKSh 17,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Kras Codon 61 Mutation Detection Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Patients diagnosed with colorectal cancer.
  • ✓Patients diagnosed with pancreatic cancer.
  • ✓Patients diagnosed with lung cancer.
  • ✓Patients where targeted therapy selection is needed.
  • ✓Patients with unexplained symptoms potentially related to cancer (e.g., weight loss, abdominal pain, changes in bowel habits, persistent cough).
02

In plain language

What this test helps you understand

This test helps guide treatment decisions, particularly for targeted therapies, in patients with certain types of cancer where KRAS mutations are relevant. It can provide insights into potential treatment response and prognosis.
The KRAS Codon 61 Mutation Detection Test is an advanced diagnostic procedure used to identify mutations in the KRAS gene. This gene plays a role in cell growth and division, and mutations can contribute to the development and progression of various cancers. This test is particularly important in oncology as it can influence treatment decisions and patient outcomes.

This test specifically looks for mutations at codon 61 of the KRAS gene. These mutations are commonly found in certain types of cancer, such as colorectal, pancreatic, and lung cancer. Identifying these mutations helps healthcare providers understand the specific characteristics of a tumor and how it might respond to different therapies, especially targeted treatments.

Patients diagnosed with specific cancers, particularly colorectal, pancreatic, or lung cancer, may benefit from this test. Discuss with your doctor if this test is appropriate for your situation. Understanding the presence or absence of a KRAS mutation can provide valuable information for planning your treatment.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationConfirm with the laboratory before booking. Ensure the sample is collected and transported according to laboratory guidelines. Fresh tissue should be shipped refrigerated within 72 hours.
SampleFresh tissue in normal saline or formalin-fixed paraffin embedded (FFPE) block. Sample must contain at least 10% tumor tissue.
MethodologyConfirm with the laboratory before booking.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test only detects mutations at codon 61 of the KRAS gene. Other mutations or genetic factors may also influence cancer progression and treatment response. Results should be interpreted in the context of the patient's overall clinical picture.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

KRAS is a gene involved in cell growth and division. Mutations in this gene can contribute to the development of certain cancers.
Identifying KRAS mutations helps doctors choose the most effective cancer treatments, especially targeted therapies, and understand the potential response to treatment.
This test is commonly used for patients with colorectal, pancreatic, and lung cancer, but may be relevant for other cancers as well. Discuss with your doctor.
A tissue sample (biopsy) is required. This can be fresh tissue or a formalin-fixed paraffin embedded block.
Results are typically available in approximately 15 days. Confirm with the laboratory before booking.
You can book the test by calling or WhatsApping us at +254711564616. We offer services in Nairobi, Mombasa, Kisumu, and home sample collection.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp